Luc Gagnon, Vice President of Vaccine Sciences and Laval, Canada Site Head, leads scientific operations at Nexelis to support vaccines and biologics development throughout the different phases of clinical trials.

With over 20 years of experience in several biotech, CRO, and pharmaceutical companies to his role, including extensive expertise in ligand binding and microbiology/virology functional assay development, qualification, and validation, Luc brings a hands-on approach to vaccine science and leadership within the organization. Research and development to clinical through all phases of clinical testing available across our vaccine science platforms, Luc and his team of cellular immunology, microbiology, and virology experts are key opinion leaders in the field and act as an extension of our partners. Their guidance and knowledge extend within our organization to our growing team of more than 150 scientists in Laval and across our global network of laboratories.

Luc received his Ph.D. in Microbiology/Immunology at Laval University, Canada with a specialty in antibiotic resistance. During his post-doctoral fellowship, Luc developed key tools to support gene therapy programs such as adenovirus, lentivirus, and baculovirus. His work directly translates to the scientific team development and laboratory testing he leads today.